Mumbai based, Entod Pharmaceuticals has launched PresVu, India’s first eye drop designed to revolutionize the treatment of presbyopia, a prevalent age-related vision impairment affecting millions of Indians.
Presbyopia is a condition that arises from the natural aging of the eye, impacting those over 40 years of age by affecting the eye's ability to focus on nearby objects. A lower concentration of pilocarpine is the active ingredient that helps contract the iris muscles, improving the eye's ability to focus on near objects and offers a potential alternative to the traditional go-to solution of reading glasses for presbyopia. The eye drops incorporate an ‘advanced dynamic buffer technology’ to ensure consistent efficacy and safety during prolonged use.
Nikkhil K Masurkar, CEO Entod Pharmaceuticals, welcomed the Drug Controller General of India's approval of PresVu as a significant stride towards transforming eye care in the country.
Although the eye drop's effect is temporary, lasting around six hours, it represents a promising alternative for those seeking freedom from reading glasses. PresVu is a prescription medicine and should not be used by individuals with iris inflammation. Potential side effects may include itching, redness, eyebrow pain and muscle spasms.
However, Doctors recommend glasses as a reliable, long-lasting solution without side effects or frequent use required for eye drops. While eye drops may help with short-term reading, there is no evidence they correct long-term vision issues.
The United States Food and Drug Administration has approved a similar pilocarpine-based eye drop for presbyopia in 2021, highlighting the global recognition of this novel approach for age-related vision challenges.
